UK Dry Eye Treatment Market Overview

UK Dry Eye Treatment Market is projected to reach USD 171.18 Million by 2028 from USD 130.70 Million in 2021, at a CAGR of 3.93% during the forecast period.

Dry eye, medically known as keratoconjunctivitis sicca, is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. This can be an indicator of either low production of tears or rapid evaporation of the film of tears on the surface of the eyes, which can be brought about by several conditions.

The growth of UK dry eye treatment market can be attributed to increasing number of geriatric population prone to various eye disorders such as dry eye and upsurge in the prevalence of disease condition such as diabetes that affects the functioning of eyes. Promising number of pipeline drugs for dry eye disease (DED) is another key factor driving the market growth. The ageing population in the country has led to an increase in the prevalence of overall dry eye disease in the country. According to the Office for National Statistics (ONS) in 2018 stated that the country’s population is ageing. The projection by the agency demonstrated that in 50 years’ time, there are likely to be an additional 8.6 million people aged 65 years and over which is a population roughly the size of London.

Furthermore, market players in the country are involved in new product launch, geography expansion and acquisition. For instance, in November 2020, Santen UK company, launched artificial tear product, and online resource platform, my eyecare. health, to tackle the UK’s growing burden of dry eye disease. Such product innovation by the company focused on the treatment of DED by the players in the country is propelling the market growth of UK dry eye treatment market.

Market Dynamics And Factors For UK Dry Eye Treatment Market

Drivers:

Rising Prevalence of Dry Eye Disease

According to a published article in PubMed in 2018, epidemiological studies from the Women’s Health Study and Physician’s Health observed that dry eye prevalence increases in women and men every five years after 50, with greater prevalence in women, compared to men. Tear dysfunction has a reported prevalence ranging from 2% to 14.2%. Older adults are particularly susceptible to inadequate tear production because of lacrimal gland dysfunction, altered reflex secretion, diminished corneal sensation, or inflammatory destruction of lacrimal glands. The aging population is more prone to various eye disorders, which is expected to propel the market growth of the UK dry eye market. Moreover, as per a study conducted by researchers in the UK in May 2020, young adults showed relatively high rates of dry eye symptoms. This factor is projected to propel market growth in the near future.

Restraints:

Limited Awareness Related To Dry Eye Disease

The awareness related to eye health is found low among the UK population, which is acting as restraining the market growth. Also, there is a lack of attention given to this disease. People often visit ophthalmologists until there are some major symptomatic conditions. A survey conducted in the UK observed that one in four adults is not found to conduct an eye test every two years as recommended by NHS. There is a high level of ignorance among the population, especially among the youngsters. This factor is limiting the growth of the UK dry eye disease market.

Opportunity:

Collaboration of Market Players

Emerging markets are anticipated to offer potential growth opportunities for the market players in the UK during the forecast period due to the rising prevalence of dry eye disease and the rising number of pipeline drugs for DED. Players in the UK dry eye market are competing to provide better patient care. Furthermore, many emerging players in the market are adopting strategies, such as acquisitions and mergers, to increase their product portfolio by launching new products and collaborations of major players with organizations. For instance, in February 2016, in Europe, Essilor International strengthened its online optical products retailing business with the acquisition of Vision Direct Group Ltd, based in the UK. Vision Direct does a majority of its business in the UK and Ireland but is also active in several other European countries. This move further strengthens Essilor International’s position in online optical retail in Europe.

Segmentation Analysis of UK Dry Eye Treatment Market

By Product, The liquid drops segment held the largest share for UK Dry Eye Treatment Market. Liquid drops are saline-containing drops for ocular route of administration. The liquid drop contains steroids, antihistamines, sympathomimetics, beta receptor blockers, parasympathomimetics, parasympatholytics, prostaglandins, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungals, or topical anesthetics. Liquid drops are generally safe for patients to use. A Gel segment is a semi-solid medication that can have properties ranging from soft and weak to hard and tough. Gels are light with a silky texture containing medical content, which reduces the puffiness of the eyes. This gel provides long-lasting lubrication to the eyes and provides relief in dry eye conditions. Liquid wipes segment is another commonly used product for dry eye condition. It is known as liquid towel or disinfecting wipes, which are small, pre-moistened pieces of paper or fabric. They are used for reducing dry eyes and maintain moisture in the eye. Eye ointment segment is a drug in semi-solid and greasy form. Once the eye ointment is applied to the patient eye, it breaks into small drops. Eye ointment mainly consists of various preservatives and medicines such as Chlorbutol, benzalkonium chloride, thiomersal, and organomercuric compounds.

By Distribution Channel, A retail pharmacy segment held the largest share for UK Dry Eye Treatment Market. Retail Pharmacy is a store where the general public can get their prescriptions filled. Retail pharmacies provide dry eye drugs, drops, and ointment to patients. E-commerce segment is projected to witness highest growth during the forecast period. E-commerce pharmacy is type of distribution channel in which dry eye-related products are suppled over the internet and sent to customers by the shipping companies, mail or online web portal. Others include wholesalers, stockists, third-party suppliers who distribute medical-related products to customers.

COVID-19 Impact Analysis on UK Dry Eye Treatment Market

Coronavirus, also known as COVID-19, first emerged in the Chinese city of Wuhan in December 2019. By the end of January 2020, the virus spread to 19 countries, and the first confirmed human-to-human transmission outside of China was recorded. This led the World Health Organization (WHO) to declare a public health emergency of international concern. COVID-19 pandemic has significantly impacted the dry eye treatment market in the UK. Patients are unable to visit ophthalmologists, which has ultimately affected the total number of patient visits. This has resulted in limiting the market growth for dry eye disease in the UK. People are opting for online consultation, by telephone or video conference with their ophthalmologists. They are relying more online for prescription and purchasing the dry eye products, which is influencing the market growth in the country.

Top Key Players Covered In UK Dry Eye Treatment Market

  • Allergan plc
  • Bausch and Lomb Pvt Ltd
  • Santen Pharmaceutical Co., Ltd
  • Otsuka pharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson Services Inc
  • Novartis AG
  • I-MED Pharma
  • Lenstore
  • Vision Direct

Key Industry Developments In The UK Dry Eye Treatment Market

In February 2020, I-MED Pharma Inc launched I-DROP which is artificial tears to control symptoms of dry eye. It is effective eye drop for hydrating and lubricating the cornea.

In December 2017, GrandVision (Parent company of Lenstore) announced the acquisition of Tesco Opticians in the UK and Ireland. By this acquisition, the company expanded its business and strengthened its growth.

UK Dry Eye Treatment Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data :

2016 to 2020

Market Size in 2021:

USD 130.70 Mn.

Forecast Period 2022-28 CAGR:

3.93%

Market Size in 2028:

USD 171.18 Mn

Segments Covered:

By Product

  • Liquid Drops
  • Gel
  • Liquid Wipes
  • Eye Ointment

By Drugs

  • Artificial Lubricant Eye Drops
  • Anti-Inflammatory Drugs
  • Autologous Serum Eye Drops

By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • Others

Key Market Drivers:

  • Rising Prevalence of Dry Eye Disease

Key Market Restraints:

  • Limited Awareness Related To Dry Eye Disease

Key Opportunities:

  • Collaboration of Market Players

Companies Covered in the report:

  • Allergan plc, Bausch and Lomb Pvt Ltd, Santen Pharmaceutical Co., Ltd, Otsuka pharmaceutical Co Ltd, and Other Major Players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Product
 3.2 By Drugs
 3.3 By End User

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: UK Dry Eye Treatment Market by Product
 5.1 UK Dry Eye Treatment Market Overview Snapshot and Growth Engine
 5.2 UK Dry Eye Treatment Market Overview
 5.3 Liquid Drops
  5.3.1 Introduction and Market Overview
  5.3.2 Key Market Trends, Growth Factors and Opportunities
  5.3.3 Impact of Covid-19
  5.3.4 Historic and Forecasted Market Size (2016-2028F)
  5.3.5 Key Market Trends, Growth Factors and Opportunities
  5.3.6 Liquid Drops: Geographic Segmentation
 5.4 Gel
  5.4.1 Introduction and Market Overview
  5.4.2 Key Market Trends, Growth Factors and Opportunities
  5.4.3 Impact of Covid-19
  5.4.4 Historic and Forecasted Market Size (2016-2028F)
  5.4.5 Key Market Trends, Growth Factors and Opportunities
  5.4.6 Gel: Geographic Segmentation
 5.5 Liquid Wipes
  5.5.1 Introduction and Market Overview
  5.5.2 Key Market Trends, Growth Factors and Opportunities
  5.5.3 Impact of Covid-19
  5.5.4 Historic and Forecasted Market Size (2016-2028F)
  5.5.5 Key Market Trends, Growth Factors and Opportunities
  5.5.6 Liquid Wipes: Geographic Segmentation
 5.6 Eye Ointment
  5.6.1 Introduction and Market Overview
  5.6.2 Key Market Trends, Growth Factors and Opportunities
  5.6.3 Impact of Covid-19
  5.6.4 Historic and Forecasted Market Size (2016-2028F)
  5.6.5 Key Market Trends, Growth Factors and Opportunities
  5.6.6 Eye Ointment: Geographic Segmentation

Chapter 6: UK Dry Eye Treatment Market by Drugs
 6.1 UK Dry Eye Treatment Market Overview Snapshot and Growth Engine
 6.2 UK Dry Eye Treatment Market Overview
 6.3 Artificial Lubricant Eye Drops
  6.3.1 Introduction and Market Overview
  6.3.2 Key Market Trends, Growth Factors and Opportunities
  6.3.3 Impact of Covid-19
  6.3.4 Historic and Forecasted Market Size (2016-2028F)
  6.3.5 Key Market Trends, Growth Factors and Opportunities
  6.3.6 Artificial Lubricant Eye Drops: Geographic Segmentation
 6.4 Anti-Inflammatory Drugs
  6.4.1 Introduction and Market Overview
  6.4.2 Key Market Trends, Growth Factors and Opportunities
  6.4.3 Impact of Covid-19
  6.4.4 Historic and Forecasted Market Size (2016-2028F)
  6.4.5 Key Market Trends, Growth Factors and Opportunities
  6.4.6 Anti-Inflammatory Drugs: Geographic Segmentation
 6.5 Autologous Serum Eye Drops
  6.5.1 Introduction and Market Overview
  6.5.2 Key Market Trends, Growth Factors and Opportunities
  6.5.3 Impact of Covid-19
  6.5.4 Historic and Forecasted Market Size (2016-2028F)
  6.5.5 Key Market Trends, Growth Factors and Opportunities
  6.5.6 Autologous Serum Eye Drops: Geographic Segmentation

Chapter 7: UK Dry Eye Treatment Market by End User
 7.1 UK Dry Eye Treatment Market Overview Snapshot and Growth Engine
 7.2 UK Dry Eye Treatment Market Overview
 7.3 Hospital Pharmacies
  7.3.1 Introduction and Market Overview
  7.3.2 Key Market Trends, Growth Factors and Opportunities
  7.3.3 Impact of Covid-19
  7.3.4 Historic and Forecasted Market Size (2016-2028F)
  7.3.5 Key Market Trends, Growth Factors and Opportunities
  7.3.6 Hospital Pharmacies: Geographic Segmentation
 7.4 Retail Pharmacies
  7.4.1 Introduction and Market Overview
  7.4.2 Key Market Trends, Growth Factors and Opportunities
  7.4.3 Impact of Covid-19
  7.4.4 Historic and Forecasted Market Size (2016-2028F)
  7.4.5 Key Market Trends, Growth Factors and Opportunities
  7.4.6 Retail Pharmacies: Geographic Segmentation
 7.5 E-Commerce
  7.5.1 Introduction and Market Overview
  7.5.2 Key Market Trends, Growth Factors and Opportunities
  7.5.3 Impact of Covid-19
  7.5.4 Historic and Forecasted Market Size (2016-2028F)
  7.5.5 Key Market Trends, Growth Factors and Opportunities
  7.5.6 E-Commerce: Geographic Segmentation
 7.6 Others
  7.6.1 Introduction and Market Overview
  7.6.2 Key Market Trends, Growth Factors and Opportunities
  7.6.3 Impact of Covid-19
  7.6.4 Historic and Forecasted Market Size (2016-2028F)
  7.6.5 Key Market Trends, Growth Factors and Opportunities
  7.6.6 Others: Geographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 UK Dry Eye Treatment Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 UK Dry Eye Treatment Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 UK Dry Eye Treatment Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 ALLERGAN PLC
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 BAUSCH AND LOMB PVT LTD
 8.4 SANTEN PHARMACEUTICAL CO.
 8.5 LTD
 8.6 OTSUKA PHARMACEUTICAL CO LTD
 8.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
 8.8 JOHNSON & JOHNSON SERVICES INC
 8.9 NOVARTIS AG
 8.10 I-MED PHARMA
 8.11 LENSTORE
 8.12 VISION DIRECT
 8.13 OTHER MAJOR PLAYERS

Chapter 9 Investment Analysis

Chapter 10 Analyst Viewpoint and Conclusion

UK Dry Eye Treatment Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data :

2016 to 2020

Market Size in 2021:

USD 130.70 Mn.

Forecast Period 2022-28 CAGR:

3.93%

Market Size in 2028:

USD 171.18 Mn

Segments Covered:

By Product

  • Liquid Drops
  • Gel
  • Liquid Wipes
  • Eye Ointment

By Drugs

  • Artificial Lubricant Eye Drops
  • Anti-Inflammatory Drugs
  • Autologous Serum Eye Drops

By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • Others

Key Market Drivers:

  • Rising Prevalence of Dry Eye Disease

Key Market Restraints:

  • Limited Awareness Related To Dry Eye Disease

Key Opportunities:

  • Collaboration of Market Players

Companies Covered in the report:

  • Allergan plc, Bausch and Lomb Pvt Ltd, Santen Pharmaceutical Co., Ltd, Otsuka pharmaceutical Co Ltd, and Other Major Players.

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. UK DRY EYE TREATMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. UK DRY EYE TREATMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. UK DRY EYE TREATMENT MARKET COMPETITIVE RIVALRY
TABLE 005. UK DRY EYE TREATMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. UK DRY EYE TREATMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. UK DRY EYE TREATMENT MARKET BY PRODUCT
TABLE 008. LIQUID DROPS MARKET OVERVIEW (2016-2028)
TABLE 009. GEL MARKET OVERVIEW (2016-2028)
TABLE 010. LIQUID WIPES MARKET OVERVIEW (2016-2028)
TABLE 011. EYE OINTMENT MARKET OVERVIEW (2016-2028)
TABLE 012. UK DRY EYE TREATMENT MARKET BY DRUGS
TABLE 013. ARTIFICIAL LUBRICANT EYE DROPS MARKET OVERVIEW (2016-2028)
TABLE 014. ANTI-INFLAMMATORY DRUGS MARKET OVERVIEW (2016-2028)
TABLE 015. AUTOLOGOUS SERUM EYE DROPS MARKET OVERVIEW (2016-2028)
TABLE 016. UK DRY EYE TREATMENT MARKET BY END USER
TABLE 017. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 018. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 019. E-COMMERCE MARKET OVERVIEW (2016-2028)
TABLE 020. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 021. UK DRY EYE TREATMENT MARKET, BY PRODUCT (2016-2028)
TABLE 022. UK DRY EYE TREATMENT MARKET, BY DRUGS (2016-2028)
TABLE 023. UK DRY EYE TREATMENT MARKET, BY END USER (2016-2028)
TABLE 024. UK DRY EYE TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 025. ALLERGAN PLC: SNAPSHOT
TABLE 026. ALLERGAN PLC: BUSINESS PERFORMANCE
TABLE 027. ALLERGAN PLC: PRODUCT PORTFOLIO
TABLE 028. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 028. BAUSCH AND LOMB PVT LTD: SNAPSHOT
TABLE 029. BAUSCH AND LOMB PVT LTD: BUSINESS PERFORMANCE
TABLE 030. BAUSCH AND LOMB PVT LTD: PRODUCT PORTFOLIO
TABLE 031. BAUSCH AND LOMB PVT LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 031. SANTEN PHARMACEUTICAL CO.: SNAPSHOT
TABLE 032. SANTEN PHARMACEUTICAL CO.: BUSINESS PERFORMANCE
TABLE 033. SANTEN PHARMACEUTICAL CO.: PRODUCT PORTFOLIO
TABLE 034. SANTEN PHARMACEUTICAL CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 034. LTD: SNAPSHOT
TABLE 035. LTD: BUSINESS PERFORMANCE
TABLE 036. LTD: PRODUCT PORTFOLIO
TABLE 037. LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. OTSUKA PHARMACEUTICAL CO LTD: SNAPSHOT
TABLE 038. OTSUKA PHARMACEUTICAL CO LTD: BUSINESS PERFORMANCE
TABLE 039. OTSUKA PHARMACEUTICAL CO LTD: PRODUCT PORTFOLIO
TABLE 040. OTSUKA PHARMACEUTICAL CO LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. TEVA PHARMACEUTICAL INDUSTRIES LTD: SNAPSHOT
TABLE 041. TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS PERFORMANCE
TABLE 042. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 043. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. JOHNSON & JOHNSON SERVICES INC: SNAPSHOT
TABLE 044. JOHNSON & JOHNSON SERVICES INC: BUSINESS PERFORMANCE
TABLE 045. JOHNSON & JOHNSON SERVICES INC: PRODUCT PORTFOLIO
TABLE 046. JOHNSON & JOHNSON SERVICES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. NOVARTIS AG: SNAPSHOT
TABLE 047. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 048. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 049. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. I-MED PHARMA: SNAPSHOT
TABLE 050. I-MED PHARMA: BUSINESS PERFORMANCE
TABLE 051. I-MED PHARMA: PRODUCT PORTFOLIO
TABLE 052. I-MED PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. LENSTORE: SNAPSHOT
TABLE 053. LENSTORE: BUSINESS PERFORMANCE
TABLE 054. LENSTORE: PRODUCT PORTFOLIO
TABLE 055. LENSTORE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. VISION DIRECT: SNAPSHOT
TABLE 056. VISION DIRECT: BUSINESS PERFORMANCE
TABLE 057. VISION DIRECT: PRODUCT PORTFOLIO
TABLE 058. VISION DIRECT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 059. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 060. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 061. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. UK DRY EYE TREATMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. UK DRY EYE TREATMENT MARKET OVERVIEW BY PRODUCT
FIGURE 012. LIQUID DROPS MARKET OVERVIEW (2016-2028)
FIGURE 013. GEL MARKET OVERVIEW (2016-2028)
FIGURE 014. LIQUID WIPES MARKET OVERVIEW (2016-2028)
FIGURE 015. EYE OINTMENT MARKET OVERVIEW (2016-2028)
FIGURE 016. UK DRY EYE TREATMENT MARKET OVERVIEW BY DRUGS
FIGURE 017. ARTIFICIAL LUBRICANT EYE DROPS MARKET OVERVIEW (2016-2028)
FIGURE 018. ANTI-INFLAMMATORY DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 019. AUTOLOGOUS SERUM EYE DROPS MARKET OVERVIEW (2016-2028)
FIGURE 020. UK DRY EYE TREATMENT MARKET OVERVIEW BY END USER
FIGURE 021. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 022. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 023. E-COMMERCE MARKET OVERVIEW (2016-2028)
FIGURE 024. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 025. UK DRY EYE TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)

Please Wait...

Frequently Asked Questions :

What would be the forecast period in the UK Dry Eye Treatment Market research report?

The forecast period in the UK Dry Eye Treatment Market research report is 2022-2028.

Who are the key players in UK Dry Eye Treatment Market?

Allergan plc, Bausch and Lomb Pvt Ltd, Santen Pharmaceutical Co., Ltd, Otsuka pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc, Novartis AG, I-MED Pharma, Lenstore, Vision Direct, Other Major Players.

What are the segments of the UK Dry Eye Treatment Market?

The UK Dry Eye Treatment Market is segmented into Product, Drugs, End User, and Region. By Product, the market is categorized into Liquid Drops, Gel, Liquid Wipes, Eye Ointment. By Drugs, the market is categorized into Artificial Lubricant Eye Drops, Anti-Inflammatory Drugs, Autologous Serum Eye Drops. By End User, the market is categorized into Hospital Pharmacies, Retail Pharmacies, E-Commerce, Others.

What is the UK Dry Eye Treatment Market?

Dry eye, medically known as keratoconjunctivitis sicca, is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. This can be an indicator of either low production of tears or rapid evaporation of the film of tears on the surface of the eyes, which can be brought about by several conditions.

How big is the UK Dry Eye Treatment Market?

UK Dry Eye Treatment Market is projected to reach USD 171.18 Million by 2028 from USD 130.70 Million in 2021, at a CAGR of 3.93% during the forecast period.